LFTs: an update A MacGilchrist PLIG meeting 31st January 2019

Size: px
Start display at page:

Download "LFTs: an update A MacGilchrist PLIG meeting 31st January 2019"

Transcription

1 LFTs: an update A MacGilchrist PLIG meeting 31 st January 2019

2 LFTs: what are we trying to achieve? (1) The case against investigation abnormal LFTs in up to 21% of the population only 1-2% develop significant liver disease The case for investigation above data based on short term follow up (3 years) liver disease is second common cause of death under 65 yrs presents at advanced stage with high mortality

3 LFTs: what are we trying to achieve? (2) Diagnosis ALD NAFLD Chronic viral hepatitis Hepatitis B Hepatitis C Haemochromatosis Autoimmune liver disease PBC AIH Biliary disease Cancer Severity liver function bilirubin albumin INR fibrosis/cirrhosis 1 0 care: indirect ratios e.g. Fib4 (2 0 care: Fibroscan, hyaluronic acid)

4 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016

5 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016

6 Changes 1: Refer to Hepatology (rather than GI) all are directed to liver unit, RIE all undergo daily etriage use SCI gateway both for traditional clinic referral and as electronic helpline 40% of hepatology referrals do not result in liver appointment no waiting list for liver clinic

7 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016

8 Changes 2: include transferrin saturation when measuring ferritin raised ferritin very common, only minority have iron overload, other explanations include alcohol XS ALD NAFLD inflammation BUT haemochromatosis is common, underdiagnosed and readily treated, so.. if raised ferritin ( > 300 ug/l) and TS (>50%), check HFE (haemochromatosis gene test)

9 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016

10 Changes 3: restrict liver immunology screen + ANA < 1/80 common in normal population only request liver immunology screen if elevated ALT or ALP (i.e. not if isolated GGT) include immunoglobulins as well as liver autoantibodies (ANA, ASMA and AMA) in liver immunology screen ignore ANA < 1/80 if other AAs negative and IgG normal

11 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016

12 Changes 4: stage fibrosis using FIB-4 rather than AST:ALT ratio indirect ratios AST: ALT ratio FIB-4 age, AST, ALT, platelets automated validated for NAFLD and Hepatitis C Others APRI (AST, platelets) NFS (age, BMI, AST, ALT, platelets, albumin, diabetes) AST > ALT: either fibrosis or ALD direct markers imaging: fibroscan, ARFI biomarkers: hyaluronic acid, ELF

13 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016

14 Changes 5: to GGT or not to GGT? pre 2012: LFTs include GGT if RIE lab (1 0 and 2 0 care) LFTs do not include GGT if WGH lab (1 0 and 2 0 care) 2012-present: LFTs include GGT if 1 0 care LFTs do not include GGT if 2 0 care future (maybe!): LFTs will not include GGT in 1 0 care or 2 0 care BUT request GGT if diagnosing/assessing/investigating isolated raised ALP NAFLD T2DM (will be included in order data set) alcohol misuse cirrhosis Audit of LFTs in primary care in Edinburgh in one month raised GGT 4,999 raised GGT alone 3,238 GGT > % (349) had an USS of these 71% (248/349) abnormal 10.6% (37) cirrhosis

15 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016

16 Changes 6: perform liver screen after single raised LFTs cost effective but apply common sense applies only to investigation of asymptomatic abnormal LFTs Changes 7: lower threshold for abnormal ALT What is an abnormal ALT? (currently > 50) men > 30 women > 19

17 Management of Asymptomatic Abnormal LFTs in Primary Care in Lothian Guideline summary December 2013 Asymptomatic abnormal ALT, GGT or ALP result Suggested thresholds for investigation when elevated on at least 2 occasions >4 weeks apart ALT > 70 ALT with an abnormal GGT/ALP (If isolated ALT check Hep B&C serology only) GGT >100 ALP >200 with an abnormal GGT (If ALP raised in isolation investigate for bone disease) (NB: If ALT/ALP/GGT persistently abnormal but below thresholds for investigation consider repeat LFTs in 1 year. If still abnormal use clinical judgment and consider patient assessment/ liver screen even if remains below thresholds) History Examination Liver screen including liver ultrasound Medication review If alcohol suspected, advise abstinence Refer to GI if any of the referral criteria* are met History Alcohol intake Drugs (prescribed, OTC, herbal remedies) Hepatitis risk factors (IVDA, sexual history, travel, ethnicity) Metabolic syndrome clues (T2DM, obesity, hypertension, hyperlipidaemia) Autoimmune disease clues (T1DM, thyroid disease, RA) Family history Examination BMI Spider naevi, Palmar erythema Palpable liver or spleen Liver Screen Abdominal Ultrasound FBC LFTs AST:ALT ratio Albumin, Caerulopasmin (if <55 years) Glucose Cholesterol Ferritin (check Transferrin sats if ferritin raised) INR Hepatitis serology HBsAg and anti-hcv Ab Immunology Anti-smooth muscle Ab, anti-nuclear Ab, anti-mitochondrial Ab Medication Review Review medications and consider discontinuing any causative drugs. If in doubt, discuss with GI/liver If the referral criteria have not been met then: The abnormal LFTs are likely to be due to either NAFLD or alcohol and there is nothing to indicate advanced fibrosis/cirrhosis These patients can continue to be safely managed in primary care with appropriate advice e.g. diet, exercise, alcohol abstinence A small number will go on to develop cirrhosis if they do not make the appropriate lifestyle changes. At present we are unable to identify which people are most likely to progress and ongoing screening for the development of fibrosis is not currently available in primary care Consider a yearly check of LFTs and AST:ALT ratio with reinforcement of lifestyle advice *GI Referral Criteria Refer to GI if any of the following apply: Diagnostic tests suggest any cause other than alcohol or NAFLD Evidence of impaired liver function: bilirubin (not due to Gilberts syndrome) INR, albumin Evidence of advanced fibrosis/cirrhosis AST : ALT ratio > 1.0 Platelets < 150 Splenomegaly ALT persistently > 200 Diagnosis or management still uncertain Review date: December 2016

18 Changes 8: 1 0 care follow-up

19 ilfts 1

20 Tayside pilot in 6 GP practices: when GP request LFTs, asked if wants liver screen? If yes, adds BMI and alcohol history to request form auto analyser selects additional tests according to results uses algorithms to advise GP of outcome: 1. likely ALD without significant fibrosis 2. likely NALFD without significant fibrosis 3. likely ALD or NAFLD with significant fibrosis 4. possible other diagnosis (with or without fibrosis) 5. unclear 1 & 2 manage in primary care 3 & 4 refer to hepatology 5 GP review (?) ilfts 2 ilfts 3 Tayside pilot completed, role out in progress, limited uptake Pilots elsewhere delayed by technical problems SG and HBs remain interested, National lead appointed, planned further pilot in GGC Watch this space, but don t hold your breath!

21 LFTs: what are we trying to achieve? (3) explanation for abnormal LFTs? or opportunistic screening for liver disease? but are LFTs a good way to detect liver disease? is a better starting point the at risk population? overweight diabetic XS alcohol is a better screening tool a fibrosis marker e.g. Fibroscan n = 79 26% abnormal Fibroscan 16% significant liver disease 8% cirrhosis

22 Offered Fibroscan to patients with XS alcohol and T2DM in selected GP practices in Nottingham

23 summary now continue to use RefHelp pathway to investigate LFTs. 2. include TS with ferritin 3. measure liver AAs and IgGs only if raised ALT or ALP 4. use SCI gateway referrals as liver helpline soon probable removal of GGT from initial LFTs 2. apply pathway to any asymptomatic LFTs 3. FIB-4 rather than AST:ALT ratio to assess liver fibrosis in the future ilfts 2. Fibroscan to screen for liver disease in at risk patients always... think why you are requesting LFTs!

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

2. Liver blood tests and what they mean p2 Acute and chronic liver screen Hepatology referral pathways for GP 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for hepatology referral 3. Raised

More information

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

2. Liver blood tests and what they mean p2 Acute and chronic liver screen 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for referral 3. Raised ALT +/- GGT p3 4. Non alcoholic fatty liver

More information

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of

More information

Investigating and Referring Incidental Findings of Abnormal Liver Tests

Investigating and Referring Incidental Findings of Abnormal Liver Tests Investigating and Referring Incidental Findings of Abnormal Liver Tests Note on Referral Guidelines: these revised guidelines are presented as a tool to aid appropriate referral and management of common

More information

Anaemia Pathway. Anaemia. Type of Anaemia Check Haematinics (Iron stores,b12,folate) Fit for endoscopies. endoscopies yes no. Non Iron Deficient

Anaemia Pathway. Anaemia. Type of Anaemia Check Haematinics (Iron stores,b12,folate) Fit for endoscopies. endoscopies yes no. Non Iron Deficient Cognitive if unable to consent, must attend clinic with next of kin to act as advocate. Rockwood Frailty Score 6 consider appropriate referral to elderly care. See attachment Anaemia Pathway Anaemia Type

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function

More information

What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon

What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon "it looks like there's something wrong.with your television set. Matt Groenig, creator of The Simpsons Probability of an abnormal screening

More information

Liver Network. Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities

Liver Network. Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities Liver Network Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities Dr Mark Hudson Dr Stuart McPherson On behalf of the North East & North Cumbria Hepatology Network 1

More information

Abnormal LFTs in migrant populations. Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital

Abnormal LFTs in migrant populations. Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital Abnormal LFTs in migrant populations Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital www.migrationobservatory.ox.ac.uk Migrants in London Migrants in London Migrants in London Common liver

More information

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

A Rational Evidence-based Approach to Abnormal Liver Tests

A Rational Evidence-based Approach to Abnormal Liver Tests A Rational Evidence-based Approach to Abnormal Liver Tests Jane D. Ricaforte-Campos, MD FPCP, FPSG, FPSDE 2013 HSP Post-graduate Course Radisson Blu Hotel, Cebu City misnomer Liver Function Tests Does

More information

Managing abnormal LFTs in Primary care

Managing abnormal LFTs in Primary care Managing abnormal LFTs in Primary care Summary guideline, April 2015 Sally Hull, Lucy Carter Managing abnormal LFTs in Primary care Draft guideline written by Dr Sally Hull and Dr Lucy Carter at CEG, with

More information

Liver Network Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities

Liver Network Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities Liver Network Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities Dr Mark Hudson Dr Stuart McPherson On behalf of the North East & North Cumbria Hepatology Network 1

More information

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice. Advice Statement 010-18 July 2018 Advice Statement What is the most accurate and cost-effective direct test (ELF test, hyaluronic acid, P3NP, Fibroscan or ARFI elastography) for detecting and staging liver

More information

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently

More information

Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018

Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018 Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018 Faculty/Presenter Disclosure Faculty: Michael Kolber Relationships with financial sponsors: Grants/Research Support: Alberta College of

More information

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated

More information

Western Health Specialist Clinics Access & Referral Guidelines

Western Health Specialist Clinics Access & Referral Guidelines Gastroenterology Specialist Clinics at Western Health: Western Health provides the following Specialist Clinics for patients who require assessment and management of Gastroenterology / Hepatology conditions.

More information

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to

More information

EVALUATION OF ABNORMAL LIVER TESTS

EVALUATION OF ABNORMAL LIVER TESTS EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical

More information

9/28/2016. Elevated Liver Function Tests: A Case Based Approach. Objectives. Identify patterns of abnormal liver function tests

9/28/2016. Elevated Liver Function Tests: A Case Based Approach. Objectives. Identify patterns of abnormal liver function tests Elevated Liver Function Tests: A Case Based Approach Terrance M. James, NP C The Oregon Clinic Hepatology 503 963 2707 tejames@orclinic.com Objectives Identify patterns of abnormal liver function tests

More information

What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology

What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology What to do about the high ALT picked up at the annual review Dr Michael Yee Consultant in Diabetes and Endocrinology Mrs DC HPC PMH Type 2 Diabetes (decades) Regular retinal screening No foot complications/neuropathy

More information

Hereditary Haemochromatosis For GPs

Hereditary Haemochromatosis For GPs Hereditary Haemochromatosis For GPs What is Hereditary Haemochromatosis? Hereditary Haemochromatosis () is a common autosomal recessive disease resulting in excessive absorption of dietary iron from the

More information

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics

More information

CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS

CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS Interpreting abnormal liver function tests (LFTs) and trying to diagnose any underlying liver disease is a common scenario in Primary

More information

Transmission of HCV in the United States (CDC estimate)

Transmission of HCV in the United States (CDC estimate) Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong

More information

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon

More information

In response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network

In response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network Evidence Note Number 82 July 2018 In response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network What is the most accurate and cost-effective direct test (ELF test, hyaluronic

More information

Case #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis

Case #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis 45 year old woman presented with abnormal liver function tests Liver Biopsy to r/o autoimmune hepatitis Further down. ANA 1: 160; ASMA 1:80 ANA 1: 160; ASMA 1:80 IgG = 14.5 g/l (upper normal range: 16)

More information

Pretreatment Evaluation

Pretreatment Evaluation Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University

More information

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008 Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended

More information

Pretreatment Evaluation

Pretreatment Evaluation Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University

More information

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal

More information

Mrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014

Mrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014 Pre-Conference Nurse s Course in partnership with Mrs Janet Catt Royal Free London NHS Foundation Trust Janet Catt MSc RN Lead Nurse Specialist Practic 1 Liver blood tests monitoring cirrhosis HIV/HCV

More information

WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT

WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT October 13, 2016 Reminder - treatment is recommended for all patients with chronic HCV infection Except short life expectancies that cannot be remediated

More information

Review: How to work up your patient with Hepatitis C

Review: How to work up your patient with Hepatitis C Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.

More information

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS

More information

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate

More information

Making the best use of liver biopsy: clinical perspective. Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham

Making the best use of liver biopsy: clinical perspective. Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham Making the best use of liver biopsy: clinical perspective Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham Trepanning most efficacious for the relief of maladies so diverse and troublesome

More information

Abnormal LFTs and NAFLD. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London

Abnormal LFTs and NAFLD. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London Abnormal LFTs and NAFLD Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London Does Liver Disease Matter? Mortality in England & Wales Liver-related

More information

Chronic Hepatitis B Infection

Chronic Hepatitis B Infection Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis

More information

Chronic Hepatitis. Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh

Chronic Hepatitis. Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh Chronic Hepatitis Andrew Bathgate Chris Bellamy Royal Infirmary of Edinburgh Autoimmune Hepatitis Annual incidence 1.9/100 000 in N Europe Prevalence 16.9/100 000 ~5% all liver transplants Female preponderance

More information

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014 Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead

More information

Hereditary Haemochromatosis (A pint too many: discussing haemochromatosis) John Lee

Hereditary Haemochromatosis (A pint too many: discussing haemochromatosis) John Lee Hereditary Haemochromatosis (A pint too many: discussing haemochromatosis) John Lee Hereditary Haemochromatosis A disorder of iron metabolism Inherited disorder Iron Essential micro-nutrient Toxicity when

More information

Abnormal LFTs GP CME 2014 Workshop Fri 55 mins. Dr Alasdair Patrick Macmurray Center GP CME 2014

Abnormal LFTs GP CME 2014 Workshop Fri 55 mins. Dr Alasdair Patrick Macmurray Center GP CME 2014 Abnormal LFTs GP CME 2014 Workshop Fri 55 mins Dr Alasdair Patrick Macmurray Center GP CME 2014 Dr Alasdair Patrick Gastroenterologist Overview Liver Function Tests Cholestasis Hepatocellular / Hepatitic

More information

Pretreatment Evaluation

Pretreatment Evaluation Pretreatment Evaluation Objective At the end of this lecture, the learner will be able to: Outline the appropriate evaluation of a person infected with HCV in order to assess the benefits and risks of

More information

Investigating general liver disease/transaminitis

Investigating general liver disease/transaminitis BHIVA Autumn Conference London 14 October 2016 Investigating general liver disease/transaminitis Emmanuel A. Tsochatzis Senior Clinical Lecturer and Consultant Hepatologist Institute for Liver and Digestive

More information

Monitoring Hepatitis C

Monitoring Hepatitis C Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody

More information

Approach to Abnormal Liver Tests

Approach to Abnormal Liver Tests Approach to Abnormal Liver Tests Scott W. Biggins, MD, MAS Assistant Professor Division of Gastroenterology UCSF Scott.Biggins@ucsf.edu (Thanks to Hal Yee, MD) This Morning s Presentation Clinical vignettes

More information

Mr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK

Mr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK Mr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK Ms Sally Bufton University Hospital Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham Mrs Janet Catt Royal Free

More information

Physical Aspects of Substance Misuse in Older People. Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford

Physical Aspects of Substance Misuse in Older People. Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford Physical Aspects of Substance Misuse in Older People Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford Areas to cover Hepatitis C Curable disease New drugs (goodbye interferon) Drug Interactions

More information

NAFLD and NASH: The Not-So-New Kids on the Block

NAFLD and NASH: The Not-So-New Kids on the Block NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an

More information

At Least 1 in 5 Patients in Your Practice Have Fatty Liver

At Least 1 in 5 Patients in Your Practice Have Fatty Liver At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease

More information

Biochemical Investigations in Liver Disease. Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya

Biochemical Investigations in Liver Disease. Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya Biochemical Investigations in Liver Disease Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya Biochemical markers Albumin ALP ALT, AST Gamma-glutamyl transpeptidase

More information

Clinical dilemmas in HBeAg-negative CHB

Clinical dilemmas in HBeAg-negative CHB Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department

More information

Non Alcohol Fatty Liver Disease (NAFLD) An information guide

Non Alcohol Fatty Liver Disease (NAFLD) An information guide TO PROVIDE THE VERY BEST CARE FOR EACH PATIENT ON EVERY OCCASION Non Alcohol Fatty Liver Disease (NAFLD) An information guide Non Alcohol Fatty Liver Disease (NAFLD) What is Non Alcohol Fatty Liver Disease?

More information

Acute Hepatitis: An Approach to Infectious and Other Causes. Mary Anne Cooper MSc, MD, MEd, FRCPC

Acute Hepatitis: An Approach to Infectious and Other Causes. Mary Anne Cooper MSc, MD, MEd, FRCPC : An Approach to Infectious and Other Causes Mary Anne Cooper MSc, MD, MEd, FRCPC Faculty: Dr. Mary Anne Cooper Relationships with commercial interests: Consulting Fees: Lupin Pharmaceuticals, Canada Objectives

More information

Liver 102: Injury and Healing

Liver 102: Injury and Healing Liver 102: Injury and Healing Dawn Pease, MSN, RN, ANP-BC Brackenridge Specialty Clinics University Medical Center Brackenridge Austin, TX Seton Healthcare Family Liver 102 Outline Biochemical patterns

More information

Approach to the Patient with Liver Disease

Approach to the Patient with Liver Disease Approach to the Patient with Liver Disease Diagnosis of liver disease Careful history taking Physical examination Laboratory tests Radiologic examination and imaging studies Liver biopsy Liver diseases

More information

Autoimmune Hepatitis in Clinical Practice

Autoimmune Hepatitis in Clinical Practice 1 Autoimmune Hepatitis in Clinical Practice Atif Zaman, MD MPH Professor of Medicine Senior Associate Dean for Clinical and Faculty Affairs School of Medicine Oregon Health & Science University Disclosure

More information

Transient elastography in chronic liver diseases of other etiologies

Transient elastography in chronic liver diseases of other etiologies 4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia

More information

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:

More information

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;

More information

Non-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology

Non-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology Non-Invasive Assessment of Liver Fibrosis Patricia Slev, PhD University of Utah Department of Pathology Disclosure Patricia Slev has no relevant financial relationships to disclose. 2 Chronic Liver Disease

More information

GI DISEASE WORKSHOP CASE STUDIES

GI DISEASE WORKSHOP CASE STUDIES GI DISEASE WORKSHOP CASE STUDIES American Academy of Insurance Medicine Triennial Course in Insurance Medicine 2012 Clifton Titcomb Jr., MD (Hannover Re) James Topic, MD (Protective Life) 1 CASE #1 Application

More information

Western Health Specialist Clinics Access & Referral Guidelines

Western Health Specialist Clinics Access & Referral Guidelines Haematology Specialist Clinics at Western Health: Western Health runs MBS funded Specialist Clinics on a Wednesday and Thursday afternoon at its Sunshine Hospital site for patients who require assessment

More information

EAST LONDON INTEGRATED CARE

EAST LONDON INTEGRATED CARE CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver

More information

Non-Invasive Testing for Liver Fibrosis

Non-Invasive Testing for Liver Fibrosis NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview

More information

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob: Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).

More information

May 2015 CLINICAL REFERENCE. gastroenterology

May 2015 CLINICAL REFERENCE. gastroenterology May 2015 CLINICAL REFERENCE gastroenterology Introduction As co-leads for the Alberta Referral Pathway for Gastroenterology (GI) and on behalf of our fellow working group, we are pleased to present this

More information

Diseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob:

Diseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob: Diseases of liver Dr. Mohamed. A. Mahdi Mob: 0123002800 4/2/2019 Cirrhosis Cirrhosis is a complication of many liver disease. Permanent scarring of the liver. A late-stage liver disease. The inflammation

More information

Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood

Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood RIUNIONE MONOTEMATICA AISF 2013 Personalizzazione della Cura in Epatologia 17-19 ottobre 2013, PISA Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood La sottoscritta dichiara di

More information

Clinical cases: HIV/HCV coinfection

Clinical cases: HIV/HCV coinfection Clinical cases: HIV/HCV coinfection José Vicente Fernández-Montero Hospital Carlos III, Madrid Case #1 General considerations about antiviral therapy CASE # 1 43 year-old, male patient Former IDU No prior

More information

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis

More information

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland Sanjiv Chopra, MD, MACP Professor of Medicine Harvard Medical School Editor In Chief Hepatology Section Up To Date Serum

More information

Module 1 Introduction of hepatitis

Module 1 Introduction of hepatitis Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand

More information

HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM

HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM EVALUATION OF LIVER FUNCTION R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM METABOLIC FUNCTION

More information

Management of acute alcoholic hepatitis

Management of acute alcoholic hepatitis Management of acute alcoholic hepatitis Yesim ALAHDAB Marmara University Hospital, Istanbul/TURKEY 5 th European Young Hepatologists Workshop August, 27-29, 2015 Moulin de Vernègues, France 1.4L ALCOHOL

More information

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry MPharm Programme Liver Biochemistry Slide 1 of 49 MPHM Liver Biochemistry Learning Outcomes Assess and evaluate the signs and symptoms of illness Assess and critically appraise a patients medication regimen,

More information

Fatty Liver Disease A growing epidemic

Fatty Liver Disease A growing epidemic Fatty Liver Disease A growing epidemic Updates in GIM for Primary Care Don C. Rockey March 9 th, 2018 Disclosures 2018 Research Funding (all to MUSC) NIH/NIDDK Actelion Pharmaceuticals Gilead Sciences

More information

CHAPTER 1. Alcoholic Liver Disease

CHAPTER 1. Alcoholic Liver Disease CHAPTER 1 Alcoholic Liver Disease Major Lesions of Alcoholic Liver Disease Alcoholic fatty liver - >90% of binge and chronic drinkers Alcoholic hepatitis precursor of cirrhosis Alcoholic cirrhosis end

More information

4/27/2018. Disclosures LIVER FUNCTION TESTS LIVER FUNCTION TESTS LIVER FUNCTION TESTS APPROACH TO THE PATIENT WITH ABNORMAL LIVER TESTS

4/27/2018. Disclosures LIVER FUNCTION TESTS LIVER FUNCTION TESTS LIVER FUNCTION TESTS APPROACH TO THE PATIENT WITH ABNORMAL LIVER TESTS APPROACH TO THE PATIENT WITH ABNORMAL TESTS Kimberly A. Brown, M.D, FAST, FAASLD, AGAF Chief, Division of Gastroenterology and Hepatology Henry Ford Hospital Henry Ford Health System Detroit, Michigan

More information

Chronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths

Chronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths Chronic Biliary Disease Dr Susan Davies & Dr Bill Griffiths Chronic Biliary Disease Terminology is confusing with pathologists and hepatologists using the same language BUT with different meanings. Chronic

More information

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? 22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical

More information

Non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease Non-alcoholic fatty liver disease Link to this article online for CPD/CME credits Naveed Sattar, 1 Ewan Forrest, 2 David Preiss 1 1 BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow

More information

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines

More information

Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY

Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY Disclosures Nothing to Disclose Assessing the patient with a new diagnosis of Hepatitis

More information

Liver Disease. Is it a big problem? Who is affected What causes it What is required. Community Hepatology Practical tips. Change of Tempo & Style

Liver Disease. Is it a big problem? Who is affected What causes it What is required. Community Hepatology Practical tips. Change of Tempo & Style Liver Disease Is it a big problem? Who is affected What causes it What is required Change of Tempo & Style Community Hepatology Practical tips Transplants ~700 HCC ~3000 Liver Failure ~5000 Deaths ~12000

More information

Objectives. Five Take Home Pearls. We Can Cure Hepatitis C. Hepatitis C Screening, Treatment and the Family Physician 10/15/2018

Objectives. Five Take Home Pearls. We Can Cure Hepatitis C. Hepatitis C Screening, Treatment and the Family Physician 10/15/2018 10/15/2018 Objectives Hepatitis C Screening, Treatment and the Family Physician Wayne Ghesquiere MD FRCPC Infectious Diseases & Internal Medicine Division of Infectious Diseases Victoria, BC At the end

More information

Fatty Liver Disease. Mark Thursz. Imperial College

Fatty Liver Disease. Mark Thursz. Imperial College Fatty Liver Disease Mark Thursz Imperial College Non-Alcoholic Fatty Liver Disease UK adult obesity (BMI>30) 1980: 6% [M], 8% [F]. 1997: 17% [M], 20% [F]. By 2004, 23.6% of men and 23.8% of women were

More information

Dr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1

Dr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1 Dr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1 No disclosures. 15/09/2018 2 Sub-Saharan Africa (SSA) has a high burden of morbidity and mortality resulting

More information

Test Profiles Time for a Change. Tony Badrick (AACB Harmonisation Committee)

Test Profiles Time for a Change. Tony Badrick (AACB Harmonisation Committee) Test Profiles Time for a Change Tony Badrick (AACB Harmonisation Committee) 1. Why Profiles 2. Profiles A. LFT B. Electrolyte C. Renal D. Bone 3. Summary Same clothes!! Harmonisation! Same car!! Harmonisation!

More information

Diagnosis and Management of PBC

Diagnosis and Management of PBC Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in

More information

BHIVA national clinical audit 2018: monitoring of adults with HIV aged 50 or over

BHIVA national clinical audit 2018: monitoring of adults with HIV aged 50 or over BHIVA national clinical audit 2018: monitoring of adults with HIV aged 50 or over Data collection for BHIVA s 2018 national clinical audit is now open until 15 June. The aim is to assess adherence to standards

More information

General Guidelines for Health professionals

General Guidelines for Health professionals General Guidelines for Health professionals Page 1 Haemochromatosis Introduction Hereditary haemochromatosis (HH) now easily screened for as most symptomatic individuals are homozygous for the C282Y mutation

More information

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Case 1 52 year-old woman, referred for liver blood tests

More information

Primary Biliary Cholangitis

Primary Biliary Cholangitis Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction

More information

World Health Organization. Western Pacific Region

World Health Organization. Western Pacific Region Standard modules for HBV 1 HBV Module 1 Hepatitis B serological markers and virology 2 Acute hepatitis HAV HBV HCV HDV HEV Case fatality Case fatality Uncommon increases with increases with age age Superinfection

More information

Invasive. Sampling error. Interobserver variability. Nondynamic evaluation of

Invasive. Sampling error. Interobserver variability. Nondynamic evaluation of How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,

More information